Clinical Trial Update: Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating anti-PD-L1 in combination with chemotherapy or chemoradiotherapy for resectable esophageal squamous cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED